GÝRÝÞ ve AMAÇ: Meme kanseri Dünya Saðlýk Örgütü’nün 2020 yýlý verilerine göre en sýk taný alan kadýn kanseridir. Çoðunlukla sporadik olmakla birlikte %5-10 oranýnda genetik yatkýnlýk zemininde ortaya çýkar. Meme kanseri ve/ veya over kanseri tanýsýyla baþvuran hastalardaki genetik yatkýnlýðý araþtýrdýðýmýz bu çalýþmamýzda amacýmýz BRCA ve non-BRCA genlerinde saptadýðýmýz varyantlarý sunmak ve Türk popülasyonuna özgü mutasyonlarý belirmektir.
YÖNTEM ve GEREÇLER: 01.01.2019-01.08.2021 tarihleri arasýnda Balýkesir Atatürk Þehir Hastanesi Týbbi Genetik polikliniðine baþvuran Herediter Meme ve/ veya Over Kanseri moleküler genetik çalýþma kriterlerini karþýlayan 120 hasta çalýþmaya dahil edildi. Öncelikle sýrasýyla BRCA1 ve BRCA2 geni dizi analizi çalýþýldý. BRCA1/2 tüm gen dizi analizi yöntemiyle mutasyon tespit edilmeyen hastalardan BRCA1 ve BRCA2 geni delesyon dublikasyon analizi ve/ veya kansere yatkýnlýkla iliþkilendirilen çoklu gen paneli çalýþýldý.
BULGULAR: Herediter Meme ve/veya Over Kanseri ile iliþkili genetik etyolojiyi araþtýrdýðýmýz bu çalýþmada BRCA ve non-BRCA genlerde %33,33 pozitif varyant saptandý. 20 hastada BRCA1 ve BRCA2 genlerinde, 20 hastada ise non-BRCA genlerinde (ATM, CHEK2, RAD50, RAD51D, STK11, MSH6, SDHA, RB1, POLD1, SMAD4, CDH1 ve CDKN22) mutasyon tespit edildi. BRCA2, ATM, RAD50, RAD51D, STK11 ve POLD1 genlerinde olmak üzere toplam 7 novel varyant tanýmlandý.
TARTIÞMA ve SONUÇ: HBOC genetik duyarlýlýk spektrumunun daha iyi anlaþýlmasý için non-BRCA genlerine özgü risklerin aydýnlatýlmasý gerekmektedir. Bu nedenle rutin BRCA genlerinden sonra çoklu gen panel testine ihtiyaç vardýr. Çalýþmamýzdaki, yeni mutasyonlarýn çoðu non-BRCA genlerinde tespit edildi. Ek olarak, iki yeni BRCA varyantý raporlandý. Ayrýca bu çalýþma ile Türk popülasyonuna özgü mutasyonlarýn belirlenmesine de katký saðlandý.

INTRODUCTION: Breast cancer is the most frequently diagnosed female cancer according to the 2020 data of the World Health Organization. It is mostly sporadic, 5-10% of which occur on the basis of genetic predisposition. In this study, we aimed to detect mutations in BRCA and non-BRCA genes in patients admitted with the diagnosis of breast cancer and/or ovarian cancer, and to identify mutations with increased frequency and variants specific to the Turkish population.
METHODS: 120 patients who applied to Balýkesir Atatürk City Hospital Medical Genetics Department between 01.01.2019-01.08.2021 and had hereditary Breast and/or Ovarian Cancer molecular genetic study criteria were included in this study. First, BRCA1/2 genes next-generation sequencing were performed on these patients, respectively. BRCA1 and BRCA2 gene deletion duplication analysis and/or multiple gene panel associated with cancer susceptibility were studied from patients with no mutations.
RESULTS: In this study, molecular genetic susceptibility study associated with Hereditary Breast and/or Ovarian Cancer 33,33 % positive variants were found in BRCA and non-BRCA genes. BRCA1/2 mutations were detected in 20 patients. In addition, non-BRCA mutations (ATM, CHEK2, RAD50, RAD51D, STK11, SDHA, RB1, POLD1, SMAD4, CDH1 and CDKN22 genes) were detected in 20 patients. We identified a total of 7 new variants in the BRCA2, ATM, RAD50, RAD51D, STK11 and POLD1 genes.
DISCUSSION AND CONCLUSION: Clarification of risks specific to non-BRCA genes is necessary for a better understanding of the HBOC genetic susceptibility spectrum. Therefore, multi-gene panel testing is needed after routine BRCA genes. In our study, most of the novel mutations were detected in non-BRCA genes. In addition, two novel BRCA variants have been reported. It also contributed to the identification of mutations specific to the Turkish population.

GÝRÝÞ ve AMAÇ: Uterin sarkomlar nadir görülen, agresif seyirli jinekolojik kanserlerden biridir. Preoperatif optimal taný testi hala bulunmamaktadýr. Çalýþmamýzýn amacý preoperatif uterin sarkomu öngörmede nötrofil-lenfosit oraný (NLR), platelet-lenfosit oraný (PLR) ve APRÝ skoru deðerlendirmektir.
YÖNTEM ve GEREÇLER: Ocak 2010 ile Aralýk 2020 tarihleri arasýnda histopatolojik sarkom tanýsý alan hastalar çalýþmaya dahil edildi. Ayný dönemde histopatolojik myom uteri tanýsý alan hastalar kontrol grubu olarak alýndý. Yaþ, vücut kitle indeksi, gravida, parite, preoperatif ortalama platelet hacmi (MPV), platelet daðýlým geniþliði (PDW), kýrmýzý hücre daðýlým geniþliði (RDW), NLR, PLR and APRÝ skoru kaydedildi.
BULGULAR: Sarkom ve myom tanýlý hastalar karþýlaþtýrýldýðýnda, sarkom hastalarýnda hemoglobin [sýrasýyla 12.3 gr/dl (6.4-15.4) ve 11.3 gr/dl (6-17), p=0.008, ], hematokrit [sýrasýyla %38.5 (22-48.7) ve %35.9 (21.4-52.1), p=0.002,] ve lenfosit seviyeleri [sýrasýyla 2.2 103/ L (0.9-13.8) ve 1.8 103/ L (1-2.6), p 0.001,] anlamlý olarak düþük, NLR [sýrasýyla 1.7 (0.2-10.1) ve 2.3 (1.4-5.9), p 0.001,] ve PLR [sýrasýyla 124 (10.9-352.1) ve 180.4 (84.9-284.3), p 0.001,] anlamlý olarak yüksek saptandý.
TARTIÞMA ve SONUÇ: Preoperatif NLR ve PLR oranlarý uterin sarkom tanýsýnda kullanýlabilecek markýrlardýr. Bu konuda kesin konuþabilmek adýna randomize kontrollü geniþ serili çalýþmalara ihtiyaç vardýr.

INTRODUCTION: Uterin sarcomas are one of the agresive gynecologic malignencies. There is still no optimal test for preoperative diagnosis of uterin sarcomas. The aim of this study was to evaluate the role of NLR, PLR, and APRI score in predicting preoperative uterine sarcoma.

METHODS: Patients operated on between January 2010 and December 2020 histopathologically diagnosed as sarcoma were included in the study group. Patients who were histopathologically diagnosed with M. uteri were included as the control group during the same period. Age, BMI (body mass index), gravida, parity, preoperative mean platelet volume (MPV), platelet distribution width (PDW), red cell distribution width (RDW), NLR,PLR and APRÝ scores were recorded.


RESULTS: When comparing patients with fibroids and sarcomas, hemoglobin [12.3 g/dl (6.4-15.4) vs. 11.3 g/dl (6-17), p=0.008, respectively], hematocrit [38.5% (22-48.7) vs. 35.9% (21.4-52.1), p=0.002, respectively] and lymphocyte levels [2.2 103/ L (0.9-13.8) vs. 1.8 103/ L (1-2.6), p 0.001, respectively] were significantly lower and NLR [1.7 (0.2-10.1) vs. 2.3 (1.4-5.9), p 0.001, respectively] and PLR [124 (10.9-352.1) vs. 180.4 (84.9-284.3), p 0.001, respectively] were significantly higher in sarcoma group. The optimal cut-off value for NLR and PLR was calculated to be 2.04 with sensitivity and specificity of 59.4% and 59.5%, respectively, and 150.7 with sensitivity and specificity of 65.6% and 64.7%, respectively.
DISCUSSION AND CONCLUSION: Preoperative NLR and PLR rates can be useful markers for diagnosing uterine sarcoma. Randomized controlled large series studies are necessary to make a definitive statement.

GÝRÝÞ ve AMAÇ: Bu yazýda, lokal ileri dil skuamöz hücreli kanserlerin (DSCC) klinikopatolojik ve demografik özellikleri, tedavi rejimleri ve saðkalým özelliklerinin sunulmasý amaçlanmaktadýr.
YÖNTEM ve GEREÇLER: Bu retrospektif çalýþma, Ocak 2005 ile Haziran 2020 arasýnda medikal onkoloji kliniðinde takip edilen, patolojik olarak doðrulanmýþ lokal ileri DSCC'li hastalarý içermektedir. Hastalarýn klinikopatolojik özellikleri ve tedavi yöntemleri hastanenin hasta kayýt veritabanýndan kaydedilmiþtir. Elde edilen veriler istatistiksel olarak karþýlaþtýrýlmýþtýr.
BULGULAR: Çalýþmaya 42 erkek ve 28 kadýn olmak üzere toplam 70 hasta dahil edildi. 5 yýllýk gene sað kalým (OS) %59 olarak bulundu. Medyan hastalýksýz sað kalým (DFS) 4.1 yýldý. Dil ön 2/3 tümörlerinde OS medyana ulaþamadý, dilin 1/3 arka tümörlerinde medyan OS 6.9 yýldý (p=0.046). Medyan OS ve medyan DFS açýsýndan yaþ gruplarý arasýnda istatistiksel anlamlý fark yoktu. Ancak dikkat çekici nokta, medyan DFS 45 yaþ ve altýndaki hastalarda, 45 yaþýn üzerindeki hastalardan (2 yýla karþý 4,5 yýl) sayýsal olarak daha kýsaydý. Ayrýca hem medyan OS hem de medyan DFS kadýnlarda numerik olarak daha kýsaydý(sýrasýyla, medyan OS: 4,1 yýla karþý 'ulaþýlamadý', p=0,075; medyan DFS: 2,2 yýla karþý 5,9 yýl, p=0,349).
TARTIÞMA ve SONUÇ: Oral kavite kanserleri ve orofaringeal kanserler baþlýklarý altýnda DSCC'yi ayrý bir baþlýk olarak inceleyen az sayýda çalýþma bulunmaktadýr. Bu anlamda bu çalýþma literatüre katký saðlayacaktýr.

INTRODUCTION: In this article, it is aimed to present the clinicopathological and demographic characteristics, treatment regimens and survival characteristics of locally advanced tongue squamous cell cancers (TSCC).
METHODS: This retrospective study included patients with histologically confirmed locally advanced TSCC followed up at the medical oncology clinic between January 2005 and June 2020. Clinicopathological features and treatment modalities of the patients were recorded from the hospital's patient registry database. The obtained data were compared statistically
RESULTS: A total of 70 patients, 42 male and 28 female, were included in the study. The 5-year OS was found to be 59%. The median disease free survival (DFS) was 4.1 years. OS could not reach the median in the 2/3 anterior tumors of the tongue, while the median OS was 6.9 years in the 1/3 posterior tumors of the tongue (p=0.046). There was no statistically significant difference between age groups in terms of median OS and median DFS. But there was a remarkable point. The median DFS was numerically shorter in patients aged 45 years and younger than in patients over 45 years of age (2 years vs. 4.5 years). Also important here was that both the median OS and the median DFS were numerically worse in women (respectively, median OS: 4.1 years vs. not reached, p=0.075; median DFS: 2.2 years vs. 5.9 years, p=0.349).
DISCUSSION AND CONCLUSION: There are few studies that examine TSCC as a separate title under these headings of oral cavity cancers and oropharyngeal cancers. In this sense, this study will contribute to the literature.

GÝRÝÞ ve AMAÇ: Çalýþmanýn amacý, multipl miyelom hastalarýnda CD23 ekspresyon durumu ile hastalarýn klinik özellikleri arasýndaki iliþkiyi deðerlendirmektir.
YÖNTEM ve GEREÇLER: Mayýs 2010 ile Aðustos 2018 tarihleri arasýnda kurumumuzda multipl miyelom tanýsý alan 196 hastanýn verilerini retrospektif olarak inceledik.
BULGULAR: CD23 negatif gruba kýyasla CD23 pozitif gurupta anlamlý olarak anemi insidansý düþük, CD20 ekspresyon insidansý yüksek ve R-ISS evre 1 hasta oraný fazla gözlendi. R-ISS ile diðer hücre yüzey markýrlarý arasýnda ise benzer bir iliþki bulunmadý.
TARTIÞMA ve SONUÇ: Sonuç olarak, aberran CD23 ekspresyonu olan multipl miyelom hastalarýnýn klinik prezentasyonlarý bazý klinik farklýlýklar göstermektedir. CD23 ekspresyonu olan MM hastalarýnýn önemli kýsmýnýn R-ISS'ye göre iyi prognostik grupta yer almasý CD23'ün prognostik deðerine dikkat çekmiþtir. MM hastalarý için rutin akým sitometri paneline CD23'ün eklenmesi düþünülebilir. Bu açýdan, CD23'ün MM'deki prognostik deðerini araþtýrmak için daha geniþ bir vaka grubunda CD23 ekspresyonunun incelenmesi gereklidir.

INTRODUCTION: The aim of the study was to evaluate the relationship between CD23 expression status and clinical features in multiple myeloma patients.
METHODS: We retrospectively analyzed the data of 196 patients diagnosed with multiple myeloma in our institution between May 2010 and August 2018.
RESULTS: Compared to the CD23 negative group, in the CD23 positive group, the incidence of anemia was significantly lower, and the incidence of CD20 expression and the rate of R-ISS stage 1 patients was significantly higher. No similar association was found between R-ISS and other cell surface markers
DISCUSSION AND CONCLUSION: In conclusion, clinical presentations of multiple myeloma patients with aberrant CD23 expression show some clinical differences from those without. The fact that MM patients with CD23 expression were clustered in the favorable prognostic group according to R-ISS drew attention to its prognostic value. For MM patients, the addition of CD23 to the routine flow cytometry panel may be considered. In this respect, examination of CD23 expression is required in a larger group of cases to assess its prognostic value in MM.

GÝRÝÞ ve AMAÇ: Bu çalýþmanýn amacý, allojenik hematopoietik kök hücre transplantasyonu (HSCT) olan hastalarda geç enfeksiyon dýþý komplikasyonlarý araþtýrmaktý.
YÖNTEM ve GEREÇLER: Ýnönü Üniversitesi Turgut Özal Týp Merkezi Hematoloji Anabilim Dalý'nda 01.02.2011-31.12.2018 tarihleri arasýnda allojenik HKHT yapýlan 143 hastanýn kayýtlarý retrospektif olarak incelendi.
BULGULAR: Çalýþmamýzda hastalarýn %68'inde geç enfeksiyon dýþý komplikasyonlar görüldü. Graft Versus Host Hastalýðý (GVHD) 43 hastada (%33) gözlendi. En yaygýn GVHD tutulum bölgeleri cilt ve karaciðerdi.
CD 34 (+) hücre sayýsýnýn kronik GVHD geliþimi (p=0,01) ve geç dönem komplikasyonlarý (p=0,016) üzerinde anlamlý etkisi olduðu belirlendi. Yüksek CD 34 (+) hücre sayýsý verilen grupta kronik GVHD ve geç komplikasyon oranlarý daha düþük bulundu.
Hastalar hazýrlýk rejimlerine göre gruplandýrýldýðýnda miyeloablatif rejim grubundaki hastalarda %78,8 oranýnda istatistiksel olarak anlamlý derecede daha fazla komplikasyon gözlendi (p=0,005).
Nakil sonrasý 90-120. günlerde primer hastalýk, böbrek komplikasyonlarý ve nörolojik komplikasyonlarýn tekrarlama oranlarýnýn daha yüksek olduðu gözlendi. Oküler ve GVHD komplikasyonlarýnýn daha sonra geliþmesi daha olasýydý. Endokrin komplikasyonlarýn hem erken hem de geç dönemlerde eþit oranda görüldüðü gözlendi.
TARTIÞMA ve SONUÇ: Allojenik HKHT yapýlan hastalarda geç komplikasyonlarýn sýk görüldüðü ve bu komplikasyonlarýn daha çok GVHD ve GVHD tedavisi ile iliþkili olduðu görüldü.

INTRODUCTION: The aim of this study was to investigate late non-infectious complications in patients with allogeneic hematopoietic stem cell transplantation (HSCT).
METHODS: The records of 143 patients who underwent allogeneic HSCT between 01.02.2011 and 31.12.2018 in Inonu University Turgut Ozal Medical Center Department of Hematology were retrospectively reviewed.
RESULTS: In our study, late non-infectious complications were seen in 68 % of the patients. Graft Versus Host Disease (GVHD) was observed in 43 patients (33%) %. The most common GVHD involvement sites were skin and liver.
It was determined that the number of CD 34 (+) cells had a significant effect on the development of chronic GVHD (p=0,01) and late stage complications (p=0,016). Chronic GVHD and late complication rates were found to be lower in the group given high CD 34 (+) cell count.
When the patients were grouped according to the preparation regimens, statistically significantly more complications were observed at the rate of 78.8% in the patients in the myeloablative regimen group (p=0.005).
It was observed that the rate of recurrence of the primary disease, renal complications and neurological complications was higher in the 90-120th days after transplantation. Ocular and GVHD complications were more likely to develop later. It was observed that endocrine complications were encountered equally in both early and late periods.

DISCUSSION AND CONCLUSION: It was seen that, late complications were common in patients who underwent allogeneic HSCT and these complications were mostly related to GVHD and GVHD treatment.

GÝRÝÞ ve AMAÇ: Bu çalýþma, ameliyat öncesi nötrofil-lenfosit oraný (NLO) ve trombosit-lenfosit oraný (PLO) düzeylerinin mide kanserinin (MK) prognozu ile iliþkisini belirlemeyi amaçladý.
YÖNTEM ve GEREÇLER: Bu, Ocak 2011-Ocak 2016 tarihleri arasýnda Eskiþehir Osmangazi Üniversitesi Týp Fakültesi Genel Cerrahi Kliniðinde yürütülen retrospektif tek merkezli bir çalýþmadýr. Çalýþmaya histolojik olarak GK tanýsý konan ve küratif cerrahi uygulanan toplam 83 hasta dahil edildi.
BULGULAR: Medyan (1.-3. çeyrek) NLO deðeri 2.62 (1.93-4) ve PLO deðeri 148.1 (117.73-221.43) idi. NLO ve PLO ile mortaliteyi tahmin etmek için yapýlan ROC analizinde uygun bir kesim noktasý elde edilmedi. Ekstrakapsüler invazyon, perinöral invazyon, lenfovasküler invazyon, cerrahi sýnýr pozitifliði, çeþitli klinik bulgular (sýzýntý, enfeksiyon ve nüks) ve düþük albümin düzeyi (p<0.05) olan MK hastalarýnda daha düþük genel saðkalým oranlarý belirlendi. Cox regresyon analizi, preoperatif NLO ve PLO'nun mortalite için anlamlý olmayan faktörler olduðunu gösterdi (sýrasýyla p=0,302 ve 0,147). Tümör boyutu, perinöral invazyon, N3 evresi, sýzýntý ve düþük albümin düzeyi mortalite için baðýmsýz prognostik belirleyiciler olarak bulundu.
TARTIÞMA ve SONUÇ: Sonuçlarýmýz, preoperatif NLO ve PLO'nun prognozla iliþkisinin olmadýðýný ve MK'li hastalarda mortalite için prognostik göstergeler olarak kullanýlamayacaðýný göstermektedir. Daha büyük tümör boyutu, perinöral invazyon, N3 evresi, sýzýntý ve hipoalbüminemi prognoz ile anlamlý olarak iliþkiliydi. Hastalarýn daha uzun süre takip edildiði ve daha büyük örneklem büyüklüklüðüne sahip ileri prospektif çalýþmalar, MK için prognostik göstergeler hakkýndaki mevcut verilerimizi doðrulamaya yardýmcý olacaktýr.

INTRODUCTION: This study aimed to determine the relationship between preoperative neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) levels with prognosis of locally advanced gastric cancers (GC).
METHODS: This was a retrospective single centre study conducted between January 2011 and January 2016 at the Department of General Surgery of XXX. A total of 83 patients histologically diagnosed with GC who received curative surgery were included in the study.
RESULTS: Median (first-third quartile) NLR value was 2.62 (1.93-4) and PLR value was 148.1 (117.73-221.43). ROC analysis did not yield optimal cut-off values for NLR and PLR to predict mortality. Lower overall survival rates were reported in GC patients with extracapsular invasion, perineural invasion, lymphovascular invasion, surgical margin positivity, various clinical findings (leakage, infection and recurrence), and lower albumin level (all, p<0.05). Cox regression analysis demonstrated that preoperative NLR and PLR were non-significant factors for mortality (p=0.302 and 0.147, respectively). Tumour size, perineural invasion, N3 stage, leakage and lower albumin level were independent prognostic determinants for mortality.
DISCUSSION AND CONCLUSION: Our results indicate that preoperative NLR and PLR were not associated with prognosis and could not be used as prognostic indicators for mortality in patients with GC. Greater tumour size, perineural invasion, N3 stage, leakage and hypoalbuminemia were significantly associated with prognosis. Further prospective studies with longer patient follow-up and larger sample sizes will help to verify our current data on prognostic indicators for GC.

GÝRÝÞ ve AMAÇ: Çalýþmamýzýn amacý, EORTC QLQ-C30 ve QLQ-HL27 anketleri yardýmýyla Türkiye genelini temsil eden bir örneklemde Hodgkin lenfoma (HL) hastalarýnda yaþam kalitesi hakkýnda veri elde etmekti.
YÖNTEM ve GEREÇLER: 2018-2020 yýllarý arasýnda, HL tanýsý almýþ 7 farklý merkezden toplam 68 hasta çalýþmaya dahil edildi. Anketler, araþtýrmaya katýlan merkezlerde hekim kontrolünde hasta tarafýndan yanýtlandý.
BULGULAR: 68 hastanýn %42.6'sý (n=29) kadýn, %57.4'ü (n=39) erkekti. Hastalarýn yaþlarý 18 ile 74 arasýnda deðiþmekte olup, ortalama 42.10±16.62 ve ortanca deðeri 40 idi. QLQ-C30 global saðlýk durumu/ yaþam kalitesi, fonksiyonel veya semptom skalalarý ve HL27 SB, PC, EI ve WF skorlarý açýsýndan yaþ alt gruplarý arasýnda anlamlý fark yoktu (tümü için, p>0.05). Kadýnlarýn kabýzlýk puanlarýnýn erkeklere göre daha yüksek olduðu belirlendi (p=0.041). Cinsiyete göre HL27 SB, PC, EI ve WF alt puanlarý açýsýndan istatistiksel olarak anlamlý fark bulunmadý (p>0.05).
TARTIÞMA ve SONUÇ: Cinsiyete göre sadece QLQ-C30 kabýzlýk alt puanlarý açýsýndan istatistiksel olarak anlamlý bir fark vardý. Kadýnlarýn kabýzlýk puanlarý erkeklerin puanlarýndan daha yüksekti. HL hastalarýnda QoL deðerlendirmesinin etkinliðini ortaya çýkarmak için daha ayrýntýlý ve geniþ popülasyon çalýþmalarýna ihtiyaç olduðu görülmektedir.

INTRODUCTION: The aim of our study is to obtain data on the quality of life (QoL) in Hodgkin lymphoma (HL) patients in a representative sample of the general population of Turkey with the help of the EORTC QLQ-C30 and QLQ-HL27 questionnaires.
METHODS: A total of 68 patients from 7 different centers diagnosed with HL between 2018-2020 were included in the study. The questionnaires were answered cross-sectionally by the patient under the control of a physician in the centers participating in the study.
RESULTS: Out of 68 patients, 42.6% (n=29) were female and 57.4% (n=39) were male. The ages of the patients ranged from 18 to 74 years, with a mean of 42.10±16.62 and with a median value of 40 years. There was no significant difference between age subgroups in terms of QLQ-C30 global health status/ QoL, functional or symptom scales and HL27 SB, PC, EI and WF scores (p>0.05, for all). It was determined that the constipation scores of females were higher than the scores of males (p=0.041). No statistically significant difference was found in terms of HL27 SB, PC, EI and WF sub-dimension scores according to gender (p>0.05).
DISCUSSION AND CONCLUSION: There was only a statistically significant difference in terms of QLQ-C30 constipation sub-dimension scores according to gender. The constipation scores of females were higher than the scores of men. More detailed and large population studies are needed to reveal the effectiveness of QoL assessment in HL patients.

GÝRÝÞ ve AMAÇ: Tamamlayýcý ve alternatif týp (TAT), kanser hastalarý tarafýndan sýklýkla kullanýlmaktadýr, ancak hematolojik kanserli hastalarda TAT kullanýmýnýn yaygýnlýðý hakkýnda çok fazla çalýþma yayýnlanmamýþtýr. Bu çalýþma, bu hasta grubunda kullanýlan TAT prevalansýný ve kullanýlan TAT tipini belirlemeyi amaçlamaktadýr
YÖNTEM ve GEREÇLER: Ankara Onkoloji Hastanesi hematoloji ve kök hücre nakli kliniðinde takip edilen hastalara TAT, sanat terapisi ve manevi destek ile ilgili bazý sorular soruldu
BULGULAR: Toplam 238 hasta katýldý. TAT kullaným yaygýnlýðý %29,4 idi. Kullanýlan en yaygýn TAT türleri fitoterapidir. Yaþ ve cinsiyet ile TAT kullanýmý arasýnda anlamlý bir iliþki yoktur. Eðitim düzeyi düþük olanlarda daha yüksek TAT kullaným oraný gözlendi. Ýl merkezlerinde yaþayanlarýn da bu tedavileri daha yüksek oranda kullandýklarý belirlendi.
TARTIÞMA ve SONUÇ: Hematolojik kanserli hastalarda TAT kullanýmýnýn diðer çalýþmalara göre daha az olduðu, hastalarýn TAT konusunda kafalarýnýn karýþtýðý ve hekimlerinden bilgi almak istedikleri dikkat çekicidir. Sanat terapisi ve manevi destek terapilerine de ilgi duyduklarý gözlemlendi.

INTRODUCTION: Complementary and alternative medicine (CAM) is often used by cancer patients, but not many studies had been published on the prevalence of CAM use in patients with hematological cancers. This study aims to determine the prevalence of CAM and type of CAM used in this group of patients.
METHODS: Patients who were followed up in Ankara Oncology Hospital hematology and stem cell transplant clinic were asked some questions about CAM, art therapy and spiritual support.
RESULTS: A total of 238 patients participated. The prevalence of CAM use was 29,4%. The most common types of CAM used is phytotherapy. There is no significant association of CAM use with age and gender. A higher rate of CAM use was observed in those with a low education level. It was found that those living in the provincial centers also used these treatments at a higher rate.
DISCUSSION AND CONCLUSION: It is noteworthy that the use of CAM is less common in patients with hematologic cancer compared to other studies, patients are confused about CAM and want to get information from their physicians. It was observed that they were also interested in art therapy and spiritual support therapies.

GÝRÝÞ ve AMAÇ: Fibrinojen-albümin oranýnýn (FAR) bazý kanserlerde prognoz ile yakýndan iliþkili olduðu bulunmuþtur. Ancak küçük hücreli akciðer kanserinde (KHAK) FAR' ýn prognostik önemi tam olarak bilinmemektedir. Bu çalýþmada FAR'ýn KHAK' deki prognostik önemini göstermeyi amaçladýk.
YÖNTEM ve GEREÇLER: KHAK tanýsý ile takip edilen 145 hasta geriye dönük olarak çalýþmaya dahil edildi. Alýcý çalýþma karakteristiði (ROC) eðrisi analizine göre FAR için optimal cutoff deðerleri belirlendi ve hastalar düþük (< 0.138) ve yüksek (≥ 0.138) FAR gruplarýna ayrýldý. C-reaktif protein (CRP)-albümin oraný (CAR), prokalsitonin-CRP oraný (PCR), prognostik beslenme indeksi (PNI) sýrasýyla 0.646, 6.1 ve 33.9'luk bir kesme noktasýna göre gruplandýrýldý. Parametrelerin progresyonsuz saðkalým (PFS) ve genel saðkalým (OS) için prognostik önemlerini deðerlendirmek için Cox regresyon analizleri kullanýldý.
BULGULAR: Hem PFS (sýrasýyla p<0,001, p: 0,027, p: 0,003) hem de OS (sýrasýyla p<0,001, p: 0,001, p<0,001) FAR, CAR, PCR yüksek olan grupta daha kýsa bulundu. Hem PFS (p: 0.020) hem de OS (p: 0.001), PNI'si yüksek olan grupta, PNI'si düþük olan gruba göre daha uzun bulundu. Çok deðiþkenli analizde FAR ve PNI, hem PFS hem de OS için baðýmsýz bir prognostik faktör olarak bulundu (sýrasýyla p: 0.039, p: 0.021; p: 0.034, p: 0.016).
TARTIÞMA ve SONUÇ: FAR ve PNI, KHAK' li hastalarda saðkalým sürelerini öngören baðýmsýz prognostik parametrelerdir.

INTRODUCTION: It has been found that fibrinogen-to-albumin ratio (FAR) is closely correlated with prognosis in some cancers. But prognostic importance of FAR in small cell lung cancer (SCLC) isn’t known completely. We aimed to show the prognostic importance of FAR in SCLC in this study.
METHODS: 145 patients followed up with diagnosis of SCLC were included in the study retrospectively. According to the receiver operating characteristic (ROC) curve analysis, the optimal cutoff values were determined for the FAR, and the patients were divided into low (< 0.138) and high (≥ 0.138) FAR groups. C-reactive protein (CRP)- albumin ratio (CAR), procalcitonin-CRP ratio (PCR), prognostic nutritional index (PNI) were grouped based on a cutoff point of 0.646, 6.1 and 33.9 respectively. Cox regression analyses were used for evaluating prognostic significances for progression-free survival (PFS) and overall survival (OS) of parameters.
RESULTS: Both PFS (p<0.001, p: 0.027, p: 0.003, respectively ) and OS (p<0.001, p: 0.001, p<0.001, respectively) were found shorter in the group with higher FAR, CAR, PCR. Both PFS (p: 0.020) and OS (p: 0.001) were found to be longer in the group with higher PNI compared to the group with low PNI. In multivariate analysis, FAR and PNI were found as an independent prognostic factor for both PFS and OS (p: 0.039, p: 0.021; p: 0.034, p: 0.016, respectively).
DISCUSSION AND CONCLUSION: FAR and PNI are independent prognostic parameters predicting survival times in patients with SCLC.

GÝRÝÞ ve AMAÇ: Kronik immün trombositopenide tedavi hedefi trombosit sayýsýný kanamayý önleyebilecek güvenli bir aralýkta tutmaktýr. Eltrombopag, trombositopeni tedavisinde oral bir trombopoietin reseptör agonistidir. Merkezimizde takipli eltrombopag kullanan toplam 79 hastanýn demografik özelliklerini, eltrombopag tedavi yanýtýný ve yan etki profilini deðerlendirdik. Bulgularýmýzý literatür verileri ile kýyaslayarak özellikle yanýt oranlarýndaki ve yan etki profilindeki farklýlýklarý ortaya koymayý amaçladýk.
YÖNTEM ve GEREÇLER: Çalýþmamýza 1 Ocak 2010 – 1 Mayýs 2021 tarihleri arasýnda merkezimizin hematoloji polikliniðine baþvuran kronik immun trombositopeni tanýsý konulan ve eltrombopag kullanan toplam 79 hasta randomize olacak þekilde retrospektif olarak deðerlendirildi. Hastalarýn demografik özellikleri, eltrombopag tedavi yanýtý, yan etki profili kaydedildi. Kategorik verilerin incelenmesinde Pearson Ki-kare testi kullanýlmýþtýr.
BULGULAR: Çalýþmamýzda eltrombopag tedavisi alan 79 hastanýn verileri retrospektif olarak incelendi ( 45 kadýn - 34 erkek, yaþ ortalamasý 49±19,1 yýl). Hastalarýn tedavi öncesi bazal trombosit sayýsý deðerlendirildiðinde ortalama deðeri 17,000/mm3 olarak hesaplandý. Eltrombopag tedavisinden sonraki tüm trombosit deðerleri incelendiðinde maksimum trombosit deðeri ortalamasý 127,000/mm3, maksimum trombosit deðerine ulaþýlan ortalama süre ise 30 gün þeklindeydi. Hastalarýn 46’sýnda (%58) komplet remisyon, 14’ünde (%17) parsiyel remisyon saðlanýrken 19’unda (%25) yanýt alýnamadýðý izlendi. Hastalarýn 16’sý (%20) uzamýþ cevaba sahipti.
TARTIÞMA ve SONUÇ: Eltrombopag tedavi kararý verilen bazal trombosit sayýsý ve tedavi yanýtlarý literatür ile benzerken, uzamýþ cevap oranlarýnýn bizim çalýþmamýzda daha fazla olduðu görüldü. Çalýþmamýzdaki karaciðer enzim takiplerindeki yükselme oraný literatürdeki verilerden daha yüksek bulunmasýna raðmen, bu sebepten ilacýn kesilmek zorunda kalýnmasýnýn oranlarý benzerdir.

INTRODUCTION: The goal of treatment in chronic immune thrombocytopenia is to keep the platelet count within a safe range that can prevent bleeding. Eltrombopag is an oral thrombopoietin receptor agonist for the treatment of thrombocytopenia. We evaluated the demographic characteristics, eltrombopag treatment response and side-effect profile of a total of 79 patients using eltrombopag with follow-up at our center. By comparing our findings with the literature data, we aimed to reveal the differences in response rates and side-effect profiles.
METHODS: A total of 79 patients who were diagnosed with chronic immune thrombocytopenia and used eltrombopag, who applied to the hematology outpatient clinic of our center between January 1, 2010 and May 1, 2021, were evaluated in a randomized retrospective manner. Demographic characteristics of the patients, eltrombopag treatment response, and side-effect profile were recorded. Pearson Chi-square test was used to analyze categorical data.
RESULTS: In our study, the data of 79 patients who received eltrombopag treatment were analyzed retrospectively (45 females - 34 males, mean age 49±19.1 years). When the basal platelet count of the patients was evaluated before the treatment, the mean value was calculated as 17,000/mm3. When all platelet values ​​after eltrombopag treatment were examined, the mean maximum platelet value was 127,000/mm3, and the mean time to reach the maximum platelet value was 30 days. Complete remission was achieved in 46 (58%) patients, partial remission was achieved in 14 (17%) patients, and 19 (25%) didn't respond. Sixteen (20%) patients had a prolonged response.
DISCUSSION AND CONCLUSION: While basal platelet count and treatment responses for eltrombopag treatment were similar to those in the literature, prolonged response rates were higher in our study. Although the rate of elevation in liver enzyme follow-ups in our study was higher than the data in the literature, the rates of having to discontinue the drug for this reason were similar.

GÝRÝÞ ve AMAÇ: Kolorektal kanser tanýsý ile opere edilen hastalarda Clavien-Dindo ve Common Terminology Criteria for Adverse Events (CTCAE) komplikasyon sýnýflamalarý kullanýlarak, erken dönem komplikasyon oranlarý, komplikasyon oluþmasýndaki risk faktörleri ve hastanede kalýþ sürelerinin karþýlaþtýrýlmasý amaçlandý.
YÖNTEM ve GEREÇLER: Mart 2019 ve Haziran 2020 tarihleri arasýnda kolorektal kanser tanýsýyla operasyona alýnan, erken dönem komplikasyon geliþen 222 hasta retrospektif olarak deðerlendirildi.Kolorektal kanser tanýsýyla operasyon uygulanan klinik takiplerinde erken dönem komplikasyon geliþen hastalar çalýþmaya alýndý. Kolorektal malignite nüksü ile opere edilen hastalar, 18 yaþýndan küçük hastalar, intraoperatif deðerlendirmede inoperabl kabul edilen hastalar ve gebeler çalýþmaya alýnmadý. Postoperatif erken dönemde geliþen komplikasyonlar, Clavien-Dindo ve CTCAE sýnýflamalarýna göre derecelendirildi. Hastalarýn demografik verilerinin, ameliyat tekniðinin, tümör yerleþiminin, neoadjuvan kemoradyoterapi öyküsünün, peroperatif transfüzyon öyküsünün, operasyonun aciliyeti, ek organ rezeksiyonunun, yandaþ hastalýklarýn, patolojik evre ve ameliyat süresinin komplikasyon üzerine etkisi karþýlaþtýrýldý.
BULGULAR: Clavien-Dindo sýnýflanmasýna göre komplikasyon geliþen I. derecede 161(%72.5) hasta, II.derecede 13(%5.9) hasta, IIIA derecede 14 (%6.3) hasta, IIIB derecede 20 (%9) hasta, IVA derecede 11 (%4.9) hasta ve V. derecede 3 (%1.4) hasta mevcuttu. CTCAE sýnýflamasýna göre komplikasyon geliþen II. derecede 162 (%73) hasta, III. derece 36 (%16.2) hasta, IV. derece 21 (%9.5) hasta ve V. derece 3 (%1.4) hasta raporlandý. Clavien-Dindo sýnýflamasýna göre erkek cinsiyet 3 kat, açýk cerrahi giriþimde 8 kat ve diabetes mellitusta 1.7 kat komplikasyon geliþme riski daha fazla bulundu. CTCAE sýnýflamasýna göre ayný seansta karaciðer rezeksiyonu uygulanmasý komplikasyon riskini 5 kat, açýk cerrahi teknikte risk 8 katýna çýkmýþtýr.
TARTIÞMA ve SONUÇ: Postoperatif komplikasyonlarý derecelendirirken iki sýnýflama sisteminin birbirine üstünlüðü olmayýp, her ikisi de cerrahi komplikasyonlarý derecelendirmede kullanýlabilir.

INTRODUCTION: The present study aimed to compare early complication rates, risk factors for complications, and hospital stay lengths in patients operated on for Colorectal cancer, by using Clavien-Dindo and Common Terminology Criteria for Adverse Events (CTCAE) complication classifications.
METHODS: 222 patients who were operated between March 2019 and June 2020 with the diagnosis of colorectal cancer and had early complications were evaluated retrospectively.Patients who were operated with the diagnosis of colorectal cancer and who developed early complications in their clinical follow-up were included in the present study. Patients who were operated for colorectal malignancy relapse, patients younger than 18 years of age, patients considered inoperable in the intraoperative evaluation, and pregnant women were excluded from the study.Complications that developed in the postoperative period were graded according to Clavien-Dindo and CTCAE classifications.
RESULTS: According to the Clavien-Dindo classification, there were 161 patients (72.5%) in grade I, 13 patients (5.9%) in grade II, 14 patients (6.3%) in grade IIIA, 20 patients (9%) in grade IIIB, 11 patients (4.9%) in grade IVA and 3 patients (1.4%) in grade V, in terms of development of complications. According to the CTCAE classification in terms of complication development, 162 (73%) patients with grade II, 36 (16.2%) patients with grade III, 21 (9.5%) patients with grade IV and 3 patients with grade V (1.4%) were reported. According to the Clavien-Dindo classification, the risk of developing complications was 3 times higher in male gender, 8 times higher in open surgical intervention, and 1.7 times higher in diabetes mellitus. According to the CTCAE classification, performing liver resection in the same session increased the risk of complications 5 times, while the use of open surgical technique increased the risk 8 times.
DISCUSSION AND CONCLUSION: : Neither classification system is superior to the other in grading postoperative complications, and both can be used to rate surgical complications.

GÝRÝÞ ve AMAÇ: Akut lösemili hastalarda retina kanamasý ile kan parametreleri arasýndaki iliþkiyi araþtýrmayý amaçladýk
YÖNTEM ve GEREÇLER: Retina kanamasý olan ve olmayan 61 akut lösemi hastasýný geriye dönük olarak araþtýrdýk ve iliþkili faktörleri analiz ettik. Hastalara detaylý göz muayenesi yapýldý. Hematolojik ve pýhtýlaþma parametreleri, fundusta retina kanamalarýnýn fark edildiði andaki verilere dayanýyordu.
BULGULAR: Çalýþma grubunu retina kanamasý olan akut miyelositik lösemili (AML) ve akut lenfositik lösemili (ALL) 30 hasta, kontrol grubunu ise retina kanamasý olmayan 31 akut lösemi hastasý oluþturdu. Hastalarýn yaklaþýk ½'sinde retina kanamasýna baðlý az görme mevcutken, diðer yarýsý titiz bir göz muayenesi ile tespit edildi. AML tanýsý retina kanamasý olan hastalarda istatistiksel olarak daha sýktý (p=0,02). Retina kanamasý olan hastalarda aktif hastalýk istatistiksel olarak daha yaygýndý (p=0.03). Retinal kanama grubunda, hastalarýn hemoglobin, hematokrit ve trombosit düzeyleri kanamasý olmayanlara göre anlamlý derecede daha düþüktü (sýrasýyla p=0,001, p=0,001 ve p=0,001). Ýki grup arasýnda lökosit deðerlerinde istatistiksel olarak anlamlý fark yoktu (p=0,634).
TARTIÞMA ve SONUÇ: Bu çalýþmada hematolojik parametreler ile retinal kanamalar arasýnda korelasyon bulduk. Aktif AML ve derin trombositopenisi olan hastalarýn göz problemlerinin çoðu asemptomatik olduðundan bunlarýn gözden kaçmamasý için göz muayenesine öncelik verilmelidir.

INTRODUCTION: We aimed to investigate the association of retinal hemorrhage and blood parameters in patients with acute leukemia
METHODS: We have retrospectively investigated sixty-one acute leukemia patients with and without retinal hemorrhages and analyzed associated factors. Patients underwent a detailed ocular examination. The hematological and coagulation parameters were based on data when the retinal hemorrhages were noticed in the fundus.
RESULTS: The study group consisted of 30 patients with acute myelocytic leukemia (AML) and acute lymphocytic leukemia (ALL) who had retinal hemorrhages and the control group consisted of 31 patients with acute leukemia without retinal hemorrhages. Approximately ½ of the patients had low vision due to retinal hemorrhage, while the other half were detected by meticulous eye examination. AML diagnosis was statistically more frequent in patients with retinal hemorrhage (p=0.02). Active disease was statistically more common in the patients with retinal hemorrhage (p=0.03). In the retinal hemorrhage group, patients had significantly lower hemoglobin, hematocrit, and platelet levels than those without hemorrhages (p=0.001, p=0.001 and p=0.001 respectively). There was no statistically significant difference in leukocytes values between two groups (p=0.634).
DISCUSSION AND CONCLUSION: In present study we found correlation between the hematological parameters and retinal hemorrhages. In patients with active AML and profound thrombocytopenia, a visual examination should be prioritized since ocular problems may go unnoticed since many patients are asymptomatic.

Giriþ: Ýnflamatuar miyofibroblastik tümör (ÝMT) memede nadir olarak yerleþir ve cerrahi rezeksiyon taný ve tedavi için yeterlidir.
Olgu Sunumu: 64 yaþýnda kadýn hasta sað memede kitle ile merkezimize baþvurdu. Mamografide, sað memede kalsifikasyon ile birlikte düzgün konturlu bir kitle mevcuttu. Üç ay sonra, kitlenin büyümesi üzerine segmental mastektomi planlandý. Patolojik özellikler, mikromorfolojik ve immünohistokimyasal boyama lezyonun IMT olduðunu doðrulamýþtýr.
Sonuç: Memenin IMT'leri nadir ve orta (nadiren metastaz yapan) malign potansiyel bir tümördür. Nüks ve metastaz riski nedeniyle negatif sýnýrlarla tam eksizyon ve düzenli takip ÝMK tedavisinde kritik bir rol oynamaktadýr.

Introduction: The inflammatory myofibroblastic tumour (IMT) rarely located in the breast and, surgýcal resection is enough for the diagnosis and treatment.
Case Report: The patient, a 64-year-old female, referred to our centre palpable mass in the right breast. Mammography demonstrated a mass of smoothed contour with calcification in the right breast. After three months later segmental mastectomy was planned as the mass grew. Pathologically features, micromorphological and immunohistochemical staining have confirmed the lesion as being breast IMT.
Conclusion: IMTs of the breast is a rare and intermediate ( rarely metastasizing) malignant potential tumour. Due to recurrence and metastasis risk, complete excision with negative margins and regular follow up plays a critical role in the treatment of IMTs.